抗苗勒氏管激素在妇科肿瘤领域的应用前景

doi:10.6040/j.issn.1671-7554.0.2018.431

摘要/Abstract

摘要： 作为评估卵巢储备功能的指标,抗苗勒氏管激素(AMH)在生殖内分泌领域已得到广泛应用。随着肿瘤治疗的发展以及人们对肿瘤生殖学的重视,妇科肿瘤患者的卵巢功能与生育问题引起了广泛关注。AMH作为月经周期中相对恒定的指标,在监测妇科肿瘤复发、评估妇科肿瘤手术损伤以及指导恶性肿瘤患者保留生育功能等方面起着至关重要的作用。

关键词: 抗苗勒氏管激素, 妇科肿瘤, 卵巢储备功能, 肿瘤标志物, 手术损伤, 保留生育功能

Abstract: Anti-Mullerian hormone has been widely used as a marker of ovarian reserve in the field of reproductive endocrinology. With the development of oncology treatment and oncofertility, ovarian function and fertility problems in gynecological oncological patients have drawn widespread attention. As a relatively constant marker in the menstrual cycle, AMH plays a crucial role in monitoring the recurrence of gynecological tumors, assessing surgical injuries, and guiding fertility preservation treatment for gynecologic malignancies.

Key words: Anti-Müllerian hormone, Gynecologic oncology, Ovarian reserve, Tumor marker, Surgical injury, Fertility preservation

中图分类号:

R737.3

曹冬焱,毕晓宁,沈铿. 抗苗勒氏管激素在妇科肿瘤领域的应用前景[J]. 山东大学学报 (医学版), 2018, 56(5): 8-12.

CAO Dongyan, BI Xiaoning, SHEN Keng. Application of anti-Mullerian hormone in gynecologic oncology[J]. Journal of Shandong University (Health Sciences), 2018, 56(5): 8-12.

参考文献

[1] Cate RL, Mattaliano RJ, Hession C, et al. Isolation of the bovine and human genes for Mullerian inhibiting substance and expression of the human gene in animal cells[J]. Cell, 1986, 45(5): 685-698.
[2] Kelsey TW, Anderson RA, Wright P, et al. Data-driven assessment of the human ovarian reserve[J]. Mol Hum Reprod, 2012, 18(2): 79-87.
[3] Jeppesen JV, Anderson RA, Kelsey TW, et al. Which follicles make the most anti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection[J]. Mol Hum Reprod, 2013, 19(8): 519-527.
[4] Dewailly D, Andersen CY, Balen A, et al. The physiology and clinical utility of anti-Mullerian hormone in women[J]. Hum Reprod Update, 2014, 20(3): 370-385.
[5] Lindhardt JM, Hagen CP, Johannsen TH, et al. Anti-mullerian hormone and its clinical use in pediatrics with special emphasis on disorders of sex development[J]. Int J Endocrinol, 2013, 2013:198698.
[6] Huang H, Wang C, Tian Q. Gonadal tumour risk in 292 phenotypic female patients with disorders of sex development containing Y chromosome or Y-derived sequence[J]. Clin Endocrinol(Oxf), 2017, 86(4): 621-627.
[7] Karkanaki A, Vosnakis C, Panidis D. The clinical significance of anti-Mullerian hormone evaluation in gynecological endocrinology[J]. Hormones(Athens), 2011, 10(2): 95-103.
[8] Farkkila A, Koskela S, Bryk S, et al. The clinical utility of serum anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumors—a comparative study with inhibin B[J]. Int J Cancer, 2015, 137(7): 1661-1671.
[9] Rey RA, Lhomme C, Marcillac I, et al. Antimullerian hormone as a serum marker of granulosa cell tumors of the ovary: comparative study with serum alpha-inhibin and estradiol[J]. Am J Obstet Gynecol, 1996, 174(3): 958-965.
[10] Haltia UM, Hallamaa M, Tapper J, et al. Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-Mullerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors[J]. Gynecol Oncol, 2017, 144(1): 83-89.
[11] McLucas B, Voorhees WD 3rd, Snyder SA. Anti-Mullerian hormone levels before and after uterine artery embolization[J]. Minim Invasive Ther Allied Technol, 2018, 27(3):186-190.
[12] Wang HY, Quan S, Zhang RL, et al. Comparison of serum anti-Mullerian hormone levels following hysterectomy and myomectomy for benign gynaecological conditions[J]. Eur J Obstet Gynecol Reprod Biol, 2013, 171(2): 368-371.
[13] Yuan H, Wang C, Wang D, et al. Comparing the effect of laparoscopic supracervical and total hysterectomy for uterine fibroids on ovarian reserve by assessing serum anti-mullerian hormone levels: a prospective cohort study[J]. J Minim Invasive Gynecol, 2015, 22(4): 637-641.
[14] Moorman PG, Myers ER, Schildkraut JM, et al. Effect of hysterectomy with ovarian preservation on ovarian function[J]. Obstet Gynecol, 2011, 118(6): 1271-1279.
[15] Trabuco EC, Moorman PG, Algeciras-Schimnich A, et al. Association of ovary-sparing hysterectomy with ovarian reserve[J]. Obstet Gynecol, 2016, 127(5): 819-827.
[16] Song T, Kim MK, Kim ML, et al. Impact of opportunistic salpingectomy on anti-Mullerian hormone in patients undergoing laparoscopic hysterectomy: a multicentre randomised controlled trial[J]. BJOG, 2017, 124(2): 314-320.
[17] Sahin C, Taylan E, Akdemir A, et al. The impact of salpingectomy and single-dose systemic methotrexate treatments on ovarian reserve in ectopic pregnancy[J]. Eur J Obstet Gynecol Reprod Biol, 2016, 205: 150-152.
[18] Salihoglu KN, Dilbaz B, Cirik DA, et al. Short-term impact of laparoscopic cystectomy on ovarian reserve tests in bilateral and unilateral endometriotic and nonendometriotic cysts[J]. J Minim Invasive Gynecol, 2016, 23(5): 719-725.
[19] Asgari Z, Rouholamin S, Hosseini R, et al. Comparing ovarian reserve after laparoscopic excision of endometriotic cysts and hemostasis achieved either by bipolar coagulation or suturing: a randomized clinical trial[J]. Arch Gynecol Obstet, 2016, 293(5): 1015-1022.
[20] Vignali M, Mabrouk M, Ciocca E, et al. Surgical excision of ovarian endometriomas: does it truly impair ovarian reserve? Long term anti-Mullerian hormone(AMH)changes after surgery[J]. J Obstet Gynaecol Res, 2015, 41(11): 1773-1778.
[21] Ferrero S, Venturini PL, Gillott DJ, et al. Hemostasis by bipolar coagulation versus suture after surgical stripping of bilateral ovarian endometriomas: a randomized controlled trial[J]. J Minim Invasive Gynecol, 2012, 19(6): 722-730.
[22] Giampaolino P, Bifulco G, Di Spiezio Sardo A, et al. Endometrioma size is a relevant factor in selection of the most appropriate surgical technique: a prospective randomized preliminary study[J]. Eur J Obstet Gynecol Reprod Biol, 2015, 195: 88-93.
[23] Green DM, Nolan VG, Kawashima T, et al. Decreased fertility among female childhood cancer survivors who received 22-27 Gy hypothalamic/pituitary irradiation: a report from the Childhood Cancer Survivor Study[J]. Fertil Steril, 2011, 95(6): 1922-1927.
[24] Barton SE, Najita JS, Ginsburg ES, et al. Infertility, infertility treatment, and achievement of pregnancy in female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study cohort[J]. Lancet Oncol, 2013, 14(9): 873-881.
[25] Bath LE, Wallace WH, Shaw MP, et al. Depletion of ovarian reserve in young women after treatment for cancer in childhood: detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound[J]. Hum Reprod, 2003, 18(11): 2368-2374.
[26] Petrek JA, Naughton MJ, Case LD, et al. Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: a prospective study[J]. J Clin Oncol, 2006, 24(7): 1045-1051.
[27] Morgan S, Anderson RA, Gourley C, et al. How do chemotherapeutic agents damage the ovary?[J]. Hum Reprod Update, 2012, 18(5): 525-535.
[28] Anderson RA, Themmen AP, Al-Qahtani A, et al. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer[J]. Hum Reprod, 2006, 21(10): 2583-2592.
[29] Dillon KE, Sammel MD, Prewitt M, et al. Pretreatment antimullerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy[J]. Fertil Steril, 2013, 99(2): 477-483.
[30] Decanter C, Morschhauser F, Pigny P, et al. Anti-Mullerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results[J]. Reprod Biomed Online, 2010, 20(2): 280-285.
[31] Bi X, Zhang J, Cao D, et al. Anti-Mullerian hormone levels in patients with gestational trophoblastic neoplasia treated with different chemotherapy regimens: a prospective cohort study[J]. Oncotarget, 2017, 8(69): 113920-113927.
[32] Rosendahl M, Andersen CY, la Cour Freiesleben N, et al. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age[J]. Fertil Steril, 2010, 94(1): 156-166.
[33] Anderson RA, Cameron DA. Pretreatment serum anti-mullerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer[J]. J Clin Endocrinol Metab, 2011, 96(5): 1336-1343.
[34] Anderson RA, Rosendahl M, Kelsey TW, et al. Pretreatment anti-Mullerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer[J]. Eur J Cancer, 2013, 49(16): 3404-3411.
[35] Elgindy E, Sibai H, Abdelghani A, et al. Protecting ovaries during chemotherapy through gonad suppression: a systematic review and meta-analysis[J]. Obstet Gynecol, 2015, 126(1): 187-195.
[36] Muraji M, Sudo T, Iwasaki S, et al. The effect of abdominal radical trachelectomy on ovarian reserve: serial changes in serum anti-mullerian hormone levels[J]. J Cancer, 2012, 3: 191-195.
[37] Naasan M, Harrity C, Rajab H, et al. Patients with cancer at the margins of reproductive age had reduced levels of anti-Mullerian hormone compared with patients experiencing infertility[J]. Int J Gynaecol Obstet, 2016, 133(2): 226-229.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed